Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

Pfizer780 enrolled

Overview

To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible second-line tumor necrosis factor α inhibitors (TNFi).

In this retrolective, multicentric study, medical charts of RA patients starting TNFi between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done after adjustment using a Cox model. Factors associated with better retention were identified by multivariate analysis. Medical charts of all patients with RA starting a first TNFα inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France) and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in detail by 2 rheumatologist investigators

Study Type

OBSERVATIONAL

Enrollment

780

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * RA defined by the 1987 ACR criteria \[18\] * first TNFα inhibitor prescribed in the previously mentioned period * TNFα inhibitor prescribed as first-line biotherapy * undergone at least one evaluation in the center after treatment initiation Exclusion Criteria: * previously received another biotherapy * TNFα inhibitor was prescribed in an RCT * refused to participate

Outcomes

Primary Outcomes

Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA

Time frame: 2 years

Secondary Outcomes

Compare retention rates of TNFα inhibitor monoclonal antibodies (adalimumab and infliximab) and the soluble receptor (etanercept)

Time frame: 4 years

Causes of discontinuing these treatments

Time frame: 4 years

Determine the factors associated with better retention of the first TNFα inhibitors

Time frame: 4 years

Compare retention rates of possible second-line TNFα inhibitors

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.